Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck presented data on aripiprazole for extended-release injectable suspension for intramuscular use (hereinafter ABILIFY MAINTENA®) in the maintenance treatment of bipolar I disorder (BP-I) at the 2016 AnnualMeeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Florida.
Citizens United for Research in Epilepsy (CURE) and Lundbeck today announced the launch of the CURE Education Enrichment Fund Scholarship Program, which is a onetime scholarship (up to $5,000) for people who are living with epilepsy, family members and caregivers. These scholarships will help advance the recipients’ personal knowledge in research, health education, advocacy and/or awareness as it relates to their experiences with epilepsy.
On November 29, 2016 Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Lundbeck received a Bronze award at the Institute of Practitioners in Advertising (IPA) Best of Health Awards in the Consumer, Social Media category for Lighter Blue. Lighter Blue, an online community, takes a unique, empathetic approach to educating about Major Depressive Disorder (MDD) in order to help people have informed conversations about their condition with their healthcare providers. The awards are steered by the IPA Healthcare Group, which is comprised of a number of IPA member healthcare agencies who look to identify, develop and promote best practice in the industry, under the umbrella of the IPA, which is a professional body for practitioners in advertising and marketing communications. The Lighter Blue campaign, featuring the cartoon character “Blue” was launched via Facebook earlier this year and has quickly evolved into a large support community for people with depression, fostering intensely loyal members who talk openly, and reach out to support each other. Visit www.facebook.com/LighterBluePage/ or www.lighterblue.com to experience Lighter Blue.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck today announced the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for the expanded labeling of ABILIFY MAINTENA® for the maintenance treatment of bipolar I disorder in adult patients is sufficiently complete to permit a substantive review and is considered filed. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of July 28, 2017, to complete its review.
The National Alliance on Mental Illness (NAMI) and the National Council for Behavioral Health (National Council), along with Otsuka America Pharmaceutical, Inc. and Lundbeck, announced the winners of the 2016 Connect 4 Mental Health™ (C4MH) Community Innovation Awards. Amidst a national landscape increasingly focused on lack of access to mental health care, C4MH advocates that change begins at home. C4MH celebrates organizations delivering community-driven, solutions-based approaches that help people with serious mental illnesses.